Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petzer, A.
Right arrow Articles by Eaves, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petzer, A.
Right arrow Articles by Eaves, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia

AL Petzer, CJ Eaves, PM Lansdorp, L Ponchio, MJ Barnett and AC Eaves

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada.

Elevated numbers of primitive Philadelphia chromosome-positive (Ph+) progenitors, including long-term culture-initiating cells (LTC-IC) as well as colony-forming cells (CFC), have been previously described in the blood of patients with chronic myeloid leukemia (CML) in chronic phase with high white blood cell counts. In the present study, which focused primarily on an analysis of circulating progenitors present in such patients at diagnosis, we discovered the frequent and occasionally exclusive presence of circulating normal (Ph-) LTC-IC, often at levels above those seen for LTC-IC in the blood of normal individuals. The presence of detectable numbers of circulating Ph- LTC-IC was independent of the fact that the same peripheral blood samples also contained elevated numbers of predominantly or exclusively Ph+ CFC. Interestingly, both the Ph+ and Ph- LTC-IC in these samples were CD34+CD71- and variably CD38- and Thy-1+, as previously documented for LTC-IC in normal marrow. Thus, neither CD38 nor Thy-1 expression was useful for discriminating between Ph+ and Ph- LTC-IC in mixed populations. Nevertheless, an association of these phenotypes with LTC- IC function did allow highly enriched (> 5% pure) suspensions of either Ph+ or Ph- LTC-IC to be obtained from selected samples of CML blood in which the initial LTC-IC population was either predominantly Ph+ or Ph- , respectively. These findings suggest that the mechanisms causing mobilization of leukemic stem cells in untreated CML patients may affect their normal counterparts. They also indicate a possible new source of autologous cells for the support of intensive therapy of CML patients. Finally, they provide a method for obtaining the most highly purified populations of Ph+ LTC-IC described to date. This method should be useful for further analyses of the molecular activities of these very primitive neoplastic cells.

Volume 88, Issue 6, pp. 2162-2171, 09/15/1996
Copyright © 1996 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
Blood, June 15, 2004; 103(12): 4666 - 4668.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. W. N. Deininger and B. J. Druker
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Pharmacol. Rev., September 1, 2003; 55(3): 401 - 423.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. W.N. Deininger, S. G. O'Brien, J. M. Ford, and B. J. Druker
Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
J. Clin. Oncol., April 15, 2003; 21(8): 1637 - 1647.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood, February 1, 2001; 97(3): 720 - 728.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. H. Brummendorf, T. L. Holyoake, N. Rufer, M. J. Barnett, M. Schulzer, C. J. Eaves, A. C. Eaves, and P. M. Lansdorp
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Blood, March 15, 2000; 95(6): 1883 - 1890.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
PNAS, October 26, 1999; 96(22): 12804 - 12809.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Holyoake, X. Jiang, C. Eaves, and A. Eaves
Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia
Blood, September 15, 1999; 94(6): 2056 - 2064.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Carlo-Stella, E. Regazzi, G. Sammarelli, S. Colla, D. Garau, A. Gazit, B. Savoldo, D. Cilloni, A. Tabilio, A. Levitzki, et al.
Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells
Blood, June 1, 1999; 93(11): 3973 - 3982.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. M. Carella, E. Lerma, M. T. Corsetti, A. Dejana, P. Basta, F. Vassallo, M. Abate, M. Soracco, F. Benvenuto, O. Figari, et al.
Autografting With Philadelphia Chromosome-Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia
Blood, March 1, 1999; 93(5): 1534 - 1539.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.D. Cashman, C.J. Eaves, A.H. Sarris, and A.C. Eaves
MCP-1, not MIP-1alpha , Is the Endogenous Chemokine That Cooperates With TGF-beta to Inhibit the Cycling of Primitive Normal but not Leukemic (CML) Progenitors in Long-Term Human Marrow Cultures
Blood, October 1, 1998; 92(7): 2338 - 2344.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.C.Y. Wang, T. Lapidot, J.D. Cashman, M. Doedens, L. Addy, D.R. Sutherland, R. Nayar, P. Laraya, M. Minden, A. Keating, et al.
High Level Engraftment of NOD/SCID Mice by Primitive Normal and Leukemic Hematopoietic Cells From Patients With Chronic Myeloid Leukemia in Chronic Phase
Blood, April 1, 1998; 91(7): 2406 - 2414.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A.L. Petzer, C.J. Eaves, M.J. Barnett, and A.C. Eaves
Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia
Blood, July 1, 1997; 90(1): 64 - 69.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020